David Mack, Ph.D.
David joined Alta Partners in 2002. David’s first investment was Angiosyn (acquired by Pfizer in 2005) where he was a Director and CEO. He currently serves on the board of directors of Aerie Pharmaceuticals, aTyr Pharma, Ceregene, Proacta Therapeutics, and Sutro Biopharma.
Prior to Alta, David co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1994 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. David was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Novartis) in the mid 1980s.
David has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 25 US patents.
He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. David received his Ph.D. from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. David holds a Bachelor of Arts in Molecular Biology from the University of California, Berkeley.